Metastatic Colorectal CancerPhase 3CodeBreaK 301NCT06252649
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
A Phase 3 study testing FOLFIRI Regimen, Sotorasib and Panitumumab in people with Metastatic Colorectal Cancer, run by Amgen at 291 sites in 35 countries.
Trial summary
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Colorectal Cancer
- What is being tested?
- FOLFIRI Regimen, Sotorasib and Panitumumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 450 participants
- Where
- 291 sitesin 35 countries
- Study dates
- 17 Jul 2024to 25 Apr 2032
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
- Central laboratory detection of KRAS p.G12C mutation.
- Measurable metastatic disease per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
- Adequate organ function.
Who cannot join
- Active, untreated brain metastases.
- Leptomeningeal disease
- Previous treatment with a KRAS p.G12C inhibitor
- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
Trial locations and contacts
291 sites in 35 countries. Contact the study team or a site near you to ask about taking part.
291 sites in 35 countries
United States26 sites, 11 recruiting
- Terminated
Georgia Cancer Specialists
Atlanta, Georgia, 30342
- Terminated
Saint Louis Cancer Care West County
Bridgeton, Missouri, 63044
- Recruiting
Ironwood Cancer and Research Centers Scottsdale
Chandler, Arizona, 85224
- Recruiting
Insight Research Institute
Chicago, Illinois, 60616
- Terminated
Henry Ford Health System
Detroit, Michigan, 48202
- Recruiting
Duke Cancer Center
Durham, North Carolina, 27710
- Terminated
Providence Saint Jude Medical Center
Fullerton, California, 92835
- Recruiting
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503
- Terminated
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521
- Recruiting
Cancer Specialists of North Florida - Southpoint
Jacksonville, Florida, 32256
- Recruiting
City of Hope National Medical Center
Long Beach, California, 90813
- Recruiting
Cancer and Blood Research Center, LLC
Los Alamitos, California, 90720
- Terminated
California Research Institute
Los Angeles, California, 90027
- Terminated
D and H Cancer Research Center
Margate, Florida, 33063
- Terminated
Minniti Center for Medical Oncology and Hematology
Mickleton, New Jersey, 08056
- Recruiting
Tennessee Oncology PLLC - Chattanooga
Nashville, Tennessee, 37203
- Recruiting
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203
- Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
- Terminated
Norwalk Hospital
Norwalk, Connecticut, 06856
- Terminated
Mid Florida Hematology and Oncology Centers PA
Orange City, Florida, 32763
- Terminated
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
- Recruiting
Pikeville Medical Center
Pikeville, Kentucky, 41501
- Terminated
FirstHealth Cancer Center
Pinehurst, North Carolina, 28374
- Terminated
Boca Raton Clinical Research Medical Center Inc
Plantation, Florida, 33322
- Terminated
Carolina Blood and Cancer Care
Rock Hill, South Carolina, 29732
- Terminated
Orchard Healthcare Research Inc
Skokie, Illinois, 60076
Japan21 sites, 21 recruiting
- Recruiting
Hyogo Cancer Center
Akashi-shi, Hyōgo, 673-8558
- Recruiting
Nippon Medical School Hospital
Bunkyo-ku, Tokyo, 113-8603
- Recruiting
Tokyo Metropolitan Komagome Hospital
Bunkyo-ku, Tokyo, 113-8677
- Recruiting
Chiba Cancer Center
Chiba, Chiba, 260-8717
- Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045
- Recruiting
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, 811-1395
- Recruiting
Kansai Medical University Hospital
Hirakata-shi, Osaka, 573-1191
- Recruiting
National Cancer Center Hospital East
Kashiwa-shi, Chiba, 277-8577
- Recruiting
St Marianna University Hospital
Kawasaki-shi, Kanagawa, 216-8511
- Recruiting
Saitama Cancer Center
Kitaadachi-gun, Saitama, 362-0806
- Recruiting
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, 135-8550
- Recruiting
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, 791-0280
- Recruiting
Aichi Cancer Center
Nagoya, Aichi-ken, 464-8681
- Recruiting
Niigata Cancer Center Hospital
Niigata, Niigata, 951-8566
- Recruiting
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006
- Recruiting
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648
- Recruiting
The University of Osaka Hospital
Suita-shi, Osaka, 565-0871
- Recruiting
Shizuoka Cancer Center
Sunto-gun, Shizuoka, 411-8777
- Recruiting
Tokushima University Hospital
Tokushima, Tokushima, 770-8503
- Recruiting
Yokohama City University Medical Center
Yokohama, Kanagawa, 232-0024
- Recruiting
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
Yokohama, Kanagawa, 241-8515
Spain20 sites, 19 recruiting
- Recruiting
Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol
Badalona, Catalonia, 08916
- Recruiting
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, 08035
- Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, 08041
- Recruiting
Hospital Universitario de Burgos
Burgos, Castille and León, 09006
- Recruiting
Hospital Universitario Reina Sofia
Córdoba, Andalusia, 14004
- Recruiting
Hospital General Universitario de Elche
Elche, Valencia, 03203
- Recruiting
Hospital Universitario Virgen de las Nieves
Granada, Andalusia, 18014
- Recruiting
Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals
L'Hospitalet de Llobregat, Catalonia, 08908
- Recruiting
Hospital General Universitario Gregorio Maranon
Madrid, 28009
- Terminated
Hospital Universitario 12 de Octubre
Madrid, 28041
- Recruiting
Hospital Universitario La Paz
Madrid, 28046
- Recruiting
Hospital Regional Universitario de Malaga
Málaga, Andalusia, 29010
- Recruiting
Complexo Hospitalario Universitario de Ourense
Ourense, Galicia, 32005
- Recruiting
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33011
- Recruiting
Hospital Universitario de Navarra
Pamplona, Navarre, 31008
- Recruiting
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008
- Recruiting
Hospital Universitario Virgen del Rocio
Seville, Andalusia, 41013
- Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Valencia, 46010
- Recruiting
Hospital General Universitario de Valencia
Valencia, Valencia, 46014
- Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Aragon, 50009
Italy19 sites, 15 recruiting
- Recruiting
Istituto Ospedaliero Fondazione Poliambulanza
Brescia, 25124
- Terminated
Ente Ospedaliero IRCCS Saverio De Bellis
Castellana Grotte, 70013
- Recruiting
Azienda Ospedaliero Universitaria Careggi
Florence, 50134
- Terminated
Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia
Foggia, 71100
- Recruiting
Ospedale Policlinico San Martino IRCCS
Genova, 16132
- Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola FC, 47014
- Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133
- Recruiting
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, 20162
- Recruiting
Azienda Ospedaliera di Rilievo Nazionale Specialistica dei Colli Monaldi
Naples, 80131
- Recruiting
Istituto Nazionale dei Tumori IRCCS Fondazione Giovanni Pascale
Naples, 80131
- Recruiting
Istituto Oncologico Veneto IRCCS
Padova, 35128
- Recruiting
Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli
Palermo, 90127
- Terminated
Azienda Sanitaria Territoriale Pesaro Urbino - Presidio San Salvatore Muraglia
Pesaro, 61122
- Recruiting
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126
- Recruiting
Azienda Unità Sanitaria Locale della Romagna Presidio ospedaliero di Ravenna
Ravenna, 48121
- Recruiting
IRCCS Istituto Clinico Humanitas
Rozzano MI, 20089
- Recruiting
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, 71013
- Recruiting
Azienda Sanitaria Universitaria Friuli Centrale Presidio Ospedaliero Santa Maria della Misericordia
Udine, 33100
- Terminated
Azienda Ospedaliera Universitaria Integrata di Verona Ospedale Civile Maggiore Borgo Trento
Verona, 37126
Brazil16 sites, 13 recruiting
- Recruiting
Fundacao pio xII Barretos
Barretos, São Paulo, 14784-400
- Recruiting
Oncoclinicas Belo Horizonte
Barretos, São Paulo, 14784-400
- Recruiting
Hospital Sirio Libanes Brasilia
Brasília, Federal District, 70200-730
- Recruiting
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Espírito Santo, 29308-020
- Recruiting
Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, 98700-000
- Terminated
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, 88301-220
- Recruiting
Liga Norte-Riograndense Contra O Cancer
Natal, Rio Grande do Norte, 59075-740
- Recruiting
Irmandade da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90050-170
- Recruiting
Associação Hospitalar Moinhos de Vento
Porto Alegre, Rio Grande do Sul, 90560-030
- Terminated
Oncoclinicas Rio de Janeiro S A
Rio de Janeiro, 22250-205
- Recruiting
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
- Terminated
Fundacao Antonio Prudente AC Camargo Cancer Center
São Paulo, São Paulo, 01246-000
- Recruiting
Instituto Cancer Sao Paulo Icesp
São Paulo, 01246-000
- Recruiting
Instituto Brasileiro de Controle do Cancer Ibcc
São Paulo, 04014-002
- Recruiting
Oncologia Rede D Or
São Paulo, 04501-000
- Recruiting
Vencer e Oncoclinica
Teresina, Piauí, 64049-200
France16 sites, 16 recruiting
- Recruiting
Centre Hospitalier Universitaire de Clermont Ferrand - Hopital Estaing
Clermont-Ferrand, 63003
- Recruiting
Hopital Henri Mondor
Créteil, 94000
- Recruiting
Centre Hospitalier Universitaire de Dijon - Hopital du Bocage
Dijon, 21079
- Recruiting
Hopital Prive Jean Mermoz
Lyon, 69008
- Recruiting
Institut regional du Cancer Montpellier
Montpellier, 34298
- Recruiting
Centre Antoine Lacassagne
Nice, 06189
- Recruiting
Hopital Europeen Georges Pompidou
Paris, 75015
- Recruiting
Hopital Saint Louis
Paris, 75475
- Recruiting
Hopital Pitie-Salpetriere
Paris, 75651
- Recruiting
Centre Hospitalier Universitaire de Bordeaux - Hopital Haut Leveque
Pessac, 33604
- Recruiting
Centre Hospitalier Universitaire de Poitiers
Poitiers, 86021
- Recruiting
Hopital Robert Debre
Reims, 51092
- Recruiting
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, 35033
- Recruiting
Institut de Cancerologie de l Ouest Rene Gauducheau
Saint-Herblain, 44805
- Recruiting
Centre Hospitalier Universitaire Nord de Saint Etienne - Hopital Nord
Saint-Priest-en-Jarez, 42270
- Recruiting
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, 54519
Argentina13 sites, 10 recruiting
- Recruiting
Hospital Britanico de Buenos Aires
Buenos Aires, C1280AEB
- Recruiting
Hospital Universitario Fundacion Favaloro
CABA, Buenos Aires, C1093AAS
- Recruiting
Instituto Argentino de Diagnóstico y Tratamiento
CABA, Buenos Aires, C1093AAS
- Recruiting
Investigaciones Clinicas Moleculares - Centro de Endocrinologia y Diabetes Dr Raul Gutman SRL
CABA, Buenos Aires, C1425BGH
- Terminated
Cemic
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1431FWO
- Recruiting
Hospital Italiano de Córdoba
Córdoba, Córdoba Province, 5000
- Terminated
Sanatorio Allende
Córdoba, Córdoba Province, X5000JHQ
- Recruiting
Clinica Universitaria Privada Reina Fabiola
Córdoba, Córdoba Province, X5004FHP
- Recruiting
Sanatorio Británico de Rosario
La Plata, Buenos Aires, 1900
- Terminated
Centro Oncologico Riojano Integral
La Rioja, F5300COE
- Recruiting
Instituto de Investigaciones clinicas de Mar del Plata
Mar del Plata, Buenos Aires, B7600FZO
- Recruiting
Exelsus Oncologia Clinica
San Miguel de Tucumán, Tucumán Province, 4000
- Recruiting
Clinica Viedma
Viedma, Río Negro Province, 8500
Turkey (Türkiye)13 sites, 10 recruiting
- Recruiting
Adana Sehir Egitim ve Arastirma Hastanesi
Adana, 01370
- Recruiting
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06230
- Recruiting
Gazi Universitesi Saglik Arastirma ve Uygulama Merkezi Gazi Hastanesi
Ankara, 06560
- Recruiting
Ankara Universitesi Tip Fakultesi Hastanesi
Ankara, 06590
- Recruiting
Ankara Bilkent Sehir Hastanesi
Ankara, 06800
- Recruiting
Trakya Universitesi Saglik Arastirma ve Uygulama Merkezi
Edirne, 22030
- Terminated
Bezmialem Vakif Universitesi Hastanesi
Istanbul, 34093
- Terminated
Bagcilar Medipol Mega Universite Hastanesi
Istanbul, 34214
- Terminated
Acibadem Altunizade Hastanesi
Istanbul, 34662
- Recruiting
Kartal Dr Lutfi Kirdar Sehir Hastanesi
Istanbul, 34865
- Recruiting
Ege Universitesi Tip Fakultesi Hastanesi
Izmir, 35100
- Recruiting
Necmettin Erbakan Universitesi Tip Fakultesi Hastanesi
Konya, 42080
- Recruiting
Inonu Universitesi Turgut Ozal Tip Merkezi
Malatya, 44280
Greece11 sites, 7 recruiting
- Terminated
General Hospital Evangelismos
Athens, 10676
- Terminated
Agios Savvas Anticancer Hospital
Athens, 11522
- Recruiting
Athens Medical Center S.A - Psychikon
Athens, 11525
- Recruiting
Aretaieio Hospital
Athens, 11528
- Recruiting
Hygeia Hospital
Athens, 15123
- Terminated
Metropolitan Hospital
Athens, 18547
- Recruiting
University Hospital of Larissa
Larissa, 41110
- Recruiting
Metaxa Anticancer Hospital
Piraeus, 18537
- Recruiting
Genesis Idiotiki Geniki Maieutiki Gynaikologiki Kliniki S.A.
Pylaia, Thessaloniki, 55535
- Terminated
Saint Lukes Hospital SA
Thessaloniki, 55236
- Recruiting
European Interbalkan Medical Center
Thessaloniki, 57001
Germany10 sites, 6 recruiting
- Recruiting
Charite - Universitaetsmedizin Berlin, Campus Virchow
Berlin, 13353
- Recruiting
Klinikum Chemnitz gGmbH
Chemnitz, 09116
- Recruiting
Universitaetsklinikum Dresden
Dresden, 01307
- Recruiting
Universitaetsklinikum Essen
Essen, 45147
- Terminated
UCT Universitaeres Zentrum fuer Tumorerkrankungen Frankfurt
Frankfurt am Main, 60488
- Terminated
Haematologisch Onkologische Praxis Eppendorf
Hamburg, 20246
- Terminated
Regional Kliniken Holding Klinikum Ludwigsburg
Ludwigsburg, 71640
- Recruiting
Klinikum der LMU Muenchen
München, 81377
- Terminated
Universitaetsklinikum Ulm
Ulm, 89081
- Recruiting
Klinikum der Stadt Wolfsburg
Wolfsburg, 38440
United Kingdom10 sites, 10 recruiting
- Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham, B15 2TH
- Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN
- Recruiting
Royal Free Hospital
London, NW3 2QG
- Recruiting
Guys Hospital
London, SE1 9RT
- Recruiting
Royal Marsden Hospital
London, SW3 6JJ
- Recruiting
Sarah Cannon Research Institute UK
London, W1G 6AD
- Recruiting
Maidstone Hospital
Maidstone, ME16 9QQ
- Recruiting
Mount Vernon Cancer Centre
Northwood, HA6 2RN
- Recruiting
Weston Park Hospital
Sheffield, S10 2SJ
- Recruiting
Royal Marsden Hospital - Sutton
Sutton, SM2 5PT
Portugal9 sites, 9 recruiting
- Recruiting
Unidade Local de Saude de Almada-Seixal, EPE - Hospital Garcia de Orta
Almada, 2801-951
- Recruiting
Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE
Coimbra, 3001-651
- Recruiting
Unidade Local de Saude de Coimbra, EPE
Coimbra, 3004-561
- Recruiting
Hospital Cuf Tejo
Lisbon, 1350-352
- Recruiting
Fundacao Champalimaud
Lisbon, 1400-038
- Recruiting
Hospital da Luz, SA
Lisbon, 1500-650
- Recruiting
Unidade Local de Saude de Santa Maria, EPE - Hospital de Santa Maria
Lisbon, 1649-035
- Recruiting
Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano
Matosinhos Municipality, 4464-513
- Recruiting
Unidade Local de Saude de Entre Douro e Vouga, EPE - Hospital de Sao Sebastiao
Santa Maria da Feira, 4520-211
Belgium8 sites, 7 recruiting
- Recruiting
Universite Catholique de Louvain Cliniques Universitaires Saint Luc
Brussels, 1200
- Recruiting
Institut Jules Bordet
Brussels, B-1070
- Recruiting
Grand Hôpital de Charleroi - Site des Viviers
Charleroi, 6060
- Recruiting
Universitair Ziekenhuis Gent
Ghent, 9000
- Recruiting
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, 3000
- Recruiting
Algemeen Ziekenhuis Sint Maarten-Emmaus vzw
Mechelen, 2800
- Recruiting
AZ Delta Campus Rumbeke
Roeselare, 8800
- Terminated
Vitaz campus Sint-Niklaas Moerland
Sint-Niklaas, 9100
Chile8 sites, 3 recruiting
- Terminated
Enroll SpA
Providencia, Santiago Metropolitan, 7500587
- Recruiting
Fundacion Arturo Lopez Perez
Santiago, 7500921
- Recruiting
Centro de Oncologia de Precision (Medicina de Precision Celerity)
Santiago, 7560907
- Terminated
Biocinetic servicios medicos limitada
Santiago, 8330336
- Recruiting
James Lind Centro de Investigacion del Cancer
Temuco, Cautín, 4800827
- Terminated
Centro de investigacion y desarrollo oncolgico Spa
Temuco, Cautín, 4810218
- Terminated
Clinical Research Chile SpA
Valdivia, 5110683
- Terminated
Clinica Redsalud Vitacura, Instituto del Cancer
Vitacura, Santiago Metropolitan, 7650018
Poland8 sites, 8 recruiting
- Recruiting
Szpitale Pomorskie spolka z ograniczona odpowiedzialnoscia
Gdynia, 81-519
- Recruiting
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej w Kielcach
Kielce, 25-734
- Recruiting
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi
Lodz, 93-513
- Recruiting
SPZOZ Opolskie Centrum Onkologii imienia prof Tadeusza Koszarowskiego w Opolu
Opole, 45-061
- Recruiting
Wielkopolskie Centrum Onkologii imienia Marii Sklodowskiej-Curie
Poznan, 61-866
- Recruiting
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
Warsaw, 02-034
- Recruiting
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i Administracji
Warsaw, 02-507
- Recruiting
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy
Warsaw, 04-141
South Korea8 sites, 4 recruiting
- Recruiting
National Cancer Center
Goyang-si, Gyeonggi-do, 10408
- Terminated
Korea University Anam Hospital
Seoul, 02841
- Terminated
Seoul National University Hospital
Seoul, 03080
- Recruiting
Severance Hospital Yonsei University Health System
Seoul, 03722
- Recruiting
Samsung Medical Center
Seoul, 06351
- Terminated
The Catholic University of Korea Seoul St Marys Hospital
Seoul, 06591
- Terminated
Korea University Guro Hospital
Seoul, 08308
- Recruiting
Asan Medical Center
Seoul, 138-736
Hungary7 sites, 6 recruiting
- Recruiting
Semmelweis Egyetem
Budapest, 1083
- Recruiting
Orszagos Onkologiai Intezet
Budapest, 1122
- Recruiting
Debreceni Egyetem Klinikai Kozpont
Debrecen, 4032
- Recruiting
Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
Gyula, 5700
- Recruiting
Somogy Varmegyei Kaposi Mor Oktato Korhaz
Kaposvár, 7400
- Terminated
Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz Nyiregyhazi Josa Andras Tagkorhaz
Nyíregyháza, 4400
- Recruiting
Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet
Szolnok, 5000
Romania7 sites, 7 recruiting
- Recruiting
Institutul Clinic Fundeni
Bucharest, 022328
- Recruiting
Institutul Oncologic Prof Dr Alexandru Trestioreanu Bucuresti
Bucharest, 022338
- Recruiting
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
Cluj-Napoca, 400015
- Recruiting
Centrul de Oncologie Sf Nectarie SRL
Craiova, 200542
- Recruiting
Institutul Regional de Oncologie Iasi
Iași, 700483
- Recruiting
Spitalul Municipal Ploiesti
Ploieşti, 100337
- Recruiting
SC Oncomed SRL
Timișoara, 300239
Australia6 sites, 5 recruiting
- Recruiting
Flinders Medical Centre
Bedford Park, South Australia, 5042
- Recruiting
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050
- Terminated
Austin Health, Austin Hospital
Heidelberg, Victoria, 3084
- Recruiting
Toowoomba Hospital
Toowoomba, Queensland, 4350
- Recruiting
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011
- Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102
Canada6 sites, 6 recruiting
- Recruiting
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, L6R 3J7
- Recruiting
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, T2N 5G2
- Recruiting
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
- Recruiting
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
- Recruiting
Sunnybrook Research Institute Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
- Recruiting
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5
Colombia6 sites, 4 recruiting
- Recruiting
Instituto Nacional de Cancerologia
Bogota, Cundinamarca, 111711
- Terminated
Centro de Tratamiento e Investigación sobre Cancer Luis Carlos Sarmiento Angulo Ctic
Bogotá, Cundinamarca, 110131
- Terminated
Fundacion Oftalmologica de Santander - Foscal
Floridablanca, Santander Department, 681004
- Recruiting
Servicios de Salud Ips Suramericana Sas - Ips Sura Industriales
Medellín, Antioquia, 050030
- Recruiting
Instituto Medico de Alta Tecnologia sas - Imat sas
Montería, Departamento de Córdoba, 230018
- Recruiting
Institucion Prestadora de Servicios de Salud Sociedad Médica Rionegro SA Somer SA
Rionegro, Antioquia, 054040
Czechia6 sites, 6 recruiting
- Recruiting
Masarykuv onkologicky ustav
Brno, 656 53
- Recruiting
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05
- Recruiting
Fakultni nemocnice Olomouc
Olomouc, 779 00
- Recruiting
Fakultni nemocnice Kralovske Vinohrady
Prague, 100 34
- Recruiting
Fakultni nemocnice v Motole
Prague, 150 06
- Recruiting
Fakultni nemocnice Bulovka
Prague, 180 81
Netherlands6 sites, 6 recruiting
- Recruiting
Nederlands Kanker Instituut - Antoni van Leeuwenhoek
Amsterdam, 1066 CX
- Recruiting
Albert Schweitzer Ziekenhuis, Locatie Dordwijk
Dordrecht, 3318 AT
- Recruiting
Medisch Spectrum Twente
Enschede, 7512 KZ
- Recruiting
Martini Ziekenhuis
Groningen, 9728 NT
- Recruiting
Maastricht Universitair Medisch Centrum
Maastricht, 6229 HX
- Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX
Austria5 sites, 3 recruiting
- Recruiting
Medizinische Universitaet Graz
Graz, 8036
- Recruiting
Ordensklinikum Linz Barmherzige Schwestern
Linz, 4010
- Terminated
Landeskrankenhaus Feldkirch
Rankweil, 6830
- Terminated
Universitaetsklinikum Allgemeines Krankenhaus Wien
Vienna, 1090
- Recruiting
Krankenhaus Wiener Neustadt
Wiener Neustadt, 2700
Bulgaria5 sites, 2 recruiting
- Terminated
Specialized Hospital for Active Treatment of Oncology - Haskovo EOOD
Haskovo, 6300
- Terminated
Multiprofile Hospital for Active Treatment Central Onco Hospital OOD
Plovdiv, 4000
- Terminated
Complex Oncology Center Plovdiv EOOD
Plovdiv, 4004
- Recruiting
Multiprofile Hospital for Active Treatment Serdikamed EOOD
Sofia, 1303
- Recruiting
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
Sofia, 1606
Denmark4 sites, 4 recruiting
- Recruiting
Aalborg Sygehus
Aalborg, 9000
- Recruiting
Aarhus University Hospital
Aarhus N, 8200
- Recruiting
Rigshospitalet
Copenhagen, 2100
- Recruiting
Odense University Hospital
Odense C, 5000
Mexico4 sites, 3 recruiting
- Recruiting
Centro Especializado en Investigacion y Tratamiento Oncologicos SC
Benito Juárez, Mexico City, 03104
- Recruiting
Health Pharma Professional Research SA de CV
Mexico City, Mexico City, 03100
- Recruiting
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, 14080
- Terminated
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, Nuevo León, 64460
Taiwan4 sites, 4 recruiting
- Recruiting
China Medical University Hospital
Taichung, 40447
- Recruiting
Taichung Veterans General Hospital
Taichung, 40705
- Recruiting
Taipei Veterans General Hospital
Taipei, 11217
- Recruiting
Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
Taoyuan, 33305
Hong Kong3 sites, 2 recruiting
- Recruiting
Queen Mary Hospital, The University of Hong Kong
Hong Kong
- Terminated
Princess Margaret Hospital
Kowloon
- Recruiting
Tuen Mun Hospital
New Territories
Estonia1 site
- Active, not recruiting
North Estonia Medical Centre Foundation
Tallinn, 13419
Puerto Rico1 site, 1 recruiting
- Recruiting
Pan American Center for Oncology Trials LLC
Rio Piedras, 00935
Slovakia1 site, 1 recruiting
- Recruiting
Vychodoslovensky onkologicky ustav, as
Košice, 041 90
Switzerland1 site
- Active, not recruiting
Universitaetsspital Zuerich
Zurich, 8091
About this study
Official title: Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
- Conditions
- Metastatic Colorectal Cancer
- Being tested
- FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb
- Keywords
- Sotorasib, Panitumumab, FOLFIRI, Bevacizumab-awwb, Oncology
- Medical subject headings
- Colorectal Neoplasms, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FOLFIRI RegimenDrug
Combination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W.
SotorasibDrug
Also called AMG 510, Lumakras, Lumykras
Immediate-release solid dosage form administered orally.
PanitumumabDrug
Also called Vectibix
Administered via IV infusion Q2W.
Bevacizumab-awwbDrug
Also called MVASI
Administered via IV infusion Q2W.
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Sotorasib + Panitumumab + FOLFIRI | Experimental | Sotorasib will be taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI will be received every 2 weeks (Q2W) via intravenous (IV) infusion. Receives: Drug: FOLFIRI Regimen; Drug: Sotorasib; Drug: Panitumumab |
| Arm B: FOLFIRI with or Without Bevacizumab-awwb | Active comparator | Participants will receive FOLFIRI Q2W with or without bevacizumab-awwb. Receives: Drug: FOLFIRI Regimen; Drug: Bevacizumab-awwb |
What is being measured
The primary outcome is the main question the study is designed to answer.
PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measured: Up to Approximately 3 Years
Secondary outcomes (18)
Overall Survival (OS)
Measured: Up to Approximately 5 Years
Objective Response Rate (ORR) per RECIST v1.1
Measured: Up to Approximately 5 Years
Objective Response (OR) per RECIST v1.1
Measured: Up to Approximately 5 Years
Duration of Response (DOR) per RECIST v1.1
Measured: Up to Approximately 5 Years
Disease Control Rate (DCR) per RECIST v1.1
Measured: Up to Approximately 5 Years
Time to Response (TTR) per RECIST v1.1
Measured: Up to Approximately 5 Years
Depth of Response per RECIST v1.1
Depth of response is measured as the percentage of tumor shrinkage calculated as the best percentage change from baseline in lesion sum diameters.
Measured: Up to Approximately 5 Years
Time to Early Tumor Shrinkage (ETS) per RECIST v1.1
Measured: Up to Approximately 5 Years
PFS Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
ORR Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
DOR Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
DCR Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
TTR Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
Depth of Response Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
Time to ETS Based on Investigator's Assessment per RECIST v1.1
Measured: Up to Approximately 5 Years
Number of Participants Experiencing Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in participant or clinical investigation subject administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment. A serious AE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital abnormality/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgment may jeopardize the patient or may require medical or surgical intervention to prevent any of the outcomes listed above.
Measured: Up to Approximately 5 Years
Pre-dose (Ctrough) Concentrations of Sotorasib
Measured: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)
Maximum Plasma Concentration (Cmax) of Sotorasib
Measured: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2024
- Study start17 Jul 2024
- Primary completion25 Sep 2028 (estimated)
- Study completion25 Apr 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Metastatic Colorectal CancerStudies of the same condition, open and under way.
- More trials run by AmgenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 450 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Amgen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- MD, Study director, Amgen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06252649
- Sponsor's protocol ID
- 20210081
- Acronym
- CodeBreaK 301
- Status last verified
- Sep 2026
- First submitted
- 15 Jan 2024
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Publications
Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067.
PubMed 39752885
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
- ClinicalTrials.gov ID
- NCT06252649
- Acronym / sponsor ID
- CodeBreaK 301 / 20210081
- Conditions
- Metastatic Colorectal Cancer
- Keywords
- Sotorasib, Panitumumab, FOLFIRI, Bevacizumab-awwb, Oncology
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 450 participants (estimated)
- Lead sponsor
- AmgenIndustry (pharma, biotech, devices)
- Study start
- 17 Jul 2024 (actual)
- Primary completion
- 25 Sep 2028 (estimated)
- Study completion
- 25 Apr 2032 (estimated)
- First posted
- 12 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: Sotorasib + Panitumumab + FOLFIRI | Experimental | Drug: FOLFIRI Regimen, Drug: Sotorasib, Drug: PanitumumabSotorasib will be taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI will be received every 2 weeks (Q2W) via intravenous (IV) infusion. |
| Arm B: FOLFIRI with or Without Bevacizumab-awwb | Active comparator | Drug: FOLFIRI Regimen, Drug: Bevacizumab-awwbParticipants will receive FOLFIRI Q2W with or without bevacizumab-awwb. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
- Central laboratory detection of KRAS p.G12C mutation.
- Measurable metastatic disease per RECIST v1.1 criteria.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
- Adequate organ function.
Key exclusion criteria (4 listed)
- Active, untreated brain metastases.
- Leptomeningeal disease
- Previous treatment with a KRAS p.G12C inhibitor
- History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FOLFIRI RegimenCombination of irinotecan, leucovorin, and 5-fluorouracil given via IV infusion Q2W. | Drug | Arm A: Sotorasib + Panitumumab + FOLFIRI, Arm B: FOLFIRI with or Without Bevacizumab-awwb |
| SotorasibAlso: AMG 510, Lumakras, LumykrasImmediate-release solid dosage form administered orally. | Drug | Arm A: Sotorasib + Panitumumab + FOLFIRI |
| PanitumumabAlso: VectibixAdministered via IV infusion Q2W. | Drug | Arm A: Sotorasib + Panitumumab + FOLFIRI |
| Bevacizumab-awwbAlso: MVASIAdministered via IV infusion Q2W. | Drug | Arm B: FOLFIRI with or Without Bevacizumab-awwb |
Primary outcome
PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Time frame: Up to Approximately 3 Years
18 secondary outcomes
Overall Survival (OS)
Time frame: Up to Approximately 5 Years
Objective Response Rate (ORR) per RECIST v1.1
Time frame: Up to Approximately 5 Years
Objective Response (OR) per RECIST v1.1
Time frame: Up to Approximately 5 Years
Duration of Response (DOR) per RECIST v1.1
Time frame: Up to Approximately 5 Years
Disease Control Rate (DCR) per RECIST v1.1
Time frame: Up to Approximately 5 Years
Time to Response (TTR) per RECIST v1.1
Time frame: Up to Approximately 5 Years
Depth of Response per RECIST v1.1
Time frame: Up to Approximately 5 Years
Time to Early Tumor Shrinkage (ETS) per RECIST v1.1
Time frame: Up to Approximately 5 Years
PFS Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
ORR Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
DOR Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
DCR Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
TTR Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
Depth of Response Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
Time to ETS Based on Investigator's Assessment per RECIST v1.1
Time frame: Up to Approximately 5 Years
Number of Participants Experiencing Adverse Events (AEs)
Time frame: Up to Approximately 5 Years
Pre-dose (Ctrough) Concentrations of Sotorasib
Time frame: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)
Maximum Plasma Concentration (Cmax) of Sotorasib
Time frame: Day 1 (pre-dose) to week 4 (post dose) on cycle 2 (one cycle = 28 days)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Derived from this study: PubMed 39752885Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067.
- AmgenTrials clinical trials websiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Related trials for Metastatic Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Not yet recruitingPhase 2
SAMe in Prevention of Oxaliplatin-associated Liver Injury
Colorectal Cancer, Liver Metastases
RecruitingPhase 1
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Metastatic Solid Tumors
Not yet recruitingPhase 1/2
A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer
CRC
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
MD study director
Amgen
291 sites in 35 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing FOLFIRI Regimen, Sotorasib and Panitumumab in people with Metastatic Colorectal Cancer, run by Amgen at 291 sites in 35 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 291 sites in United States, Japan, Spain, Italy, Brazil and 30 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amgen Call Center (866-572-6436, medinfo@amgen.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) (time frame: Up to Approximately 3 Years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06252649, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.